Purchase Order 140D0426P0305
Award Date 9/29/26
Potential Completion Date 9/28/27
Potential Value $80K
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Rockville, MD 20850, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Other Statutory Authority
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Cancer Institute awarded a firm fixed-price purchase order to Illumina, Inc. for a DRAGEN Server v4 bioinformatics system and related components and services on May 26, 2026, in the amount of $33,721.45. The order carries no set-aside designation. Place of performance is San Diego, California 92122. The DRAGEN Server v4 (Catalog Number 20032797) includes pre-installed Dragen TruSight Oncology 500 and TSO500 ctDNA analysis software, comprehensive maintenance with on-site and...
- This contract was awarded by the National Cancer Institute (NCI), Center for Biomedical Informatics and Information Technology (CBIIT) to Illumina, Inc., a biotechnology company specializing in genetic sequencing and analysis technologies. The $79,432 firm-fixed-price contract is for the purchase of two annual software licenses for Illumina's DRAGEN Server processors with 250,000GB throughput capacity, along with two annual DRAGEN Server Advance Exchange Support Plans. The contract supports...
- This firm fixed price purchase order was awarded to Illumina, Inc. by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), for the deployment of two Illumina DRAGEN Server v4 systems and associated licenses. The total ceiling value of the contract is $200,500.00, with a period of performance through October 26, 2025. The original solicitation indicates that the NCI requires the DRAGEN processors to support its Whole Genome and Whole Exome Data Processing...
- The Department of Health and Human Services National Institutes of Health National Human Genome Research Institute awarded a $15,000 purchase order to Illumina, Inc. to provide DRAGEN CS LVL 1 LICENSE THROUGHPUT OF 100,000GB under contract number E21C6L5011010032. The one-year contract, which runs from July 2025 through July 2026, calls for Illumina to deliver genomic sequencing software licensing and throughput on a firm fixed price basis, to be billed quarterly in arrears. As the prime...
- The Department of Health and Human Services National Institutes of Health National Human Genome Research Institute awarded a firm fixed price purchase order valued at twenty thousand two hundred ninety-eight dollars and ninety-nine cents ($20,298.99) to Illumina, Inc. to provide a one-year license for the DRAGEN CS Level 1 throughput of one hundred thousand gigabytes. The license will be delivered under a thirteen point six month period running from May seventh, two thousand twenty-one through...
- <p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $20,987.00 on August 31, 2017, with final completion scheduled for March 19, 2018. Performance takes place in Bethesda, Maryland. The order covers sequencing instruments, reagents, consumables, or bioinformatics software—Illumina's core product portfolio for federal genomic research applications. Pricing is firm fixed price with no set-aside applied.</p>
- This firm-fixed-price purchase order was awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to Illumina, Inc. The contract is for a DRAGEN GCP Level 4 Service License to enable NIDA's Neurodegenerative Diseases Research Section to process high-quality genome data from 10,000 patients with neurodegenerative diseases. The DRAGEN platform performs optimized algorithms for alignment, variant calling, and other advanced genomic analyses....
- The National Cancer Institute awarded a purchase order to Illumina, Inc. for an Illumina MiSeq i100 Series System on June 1, 2026, with a ceiling value of $111,115.79 and an ultimate completion date of August 24, 2026. The system is firm fixed price with no set-aside designation. Place of performance is Bethesda, Maryland. The acquisition was conducted as a sole-source procurement under FAR 6.302-1 authority through the Interior Business Center, with Illumina identified as the sole capable...
- This federal contract award, valued at $15,000.00, was issued by the National Human Genome Research Institute (NHGRI) to Illumina, Inc., a manufacturer of sequencing and genomic analysis instruments and reagents. The contract is for a DRAGEN CS Level 1 License with a throughput of 100,000GB, with a period of performance from July 25, 2024 to July 24, 2025. The contract is a firm fixed price purchase order and does not have a set-aside designation. Illumina has previously received prime federal...
- The National Institutes of Health National Institute on Aging awarded a $81,531 firm fixed price purchase order to Illumina, Inc. for a NEXTSEQ2000 BRONZE SUPPORT PLAN and DRAGEN LICENSE. The place of performance is Baltimore, Maryland. Illumina is a manufacturer and provider of sequencing and array-based solutions for genetic and genomic analysis. This award supports the National Institute on Aging's genomic sequencing and analysis efforts through the provision of Illumina's NEXTSEQ2000...